Sionna Therapeutics Inc. (SION)
Sionna Therapeutics Inc. (SION) Stock Price, Analysis & Data
| Bid | 35.98 |
| Market Cap | 230.27M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -97.38M |
| Beta | n/a |
| EPS (ttm) | -2.15 |
| PE Ratio (ttm) | n/a |
| Forward PE | -2.02 |
| P/B (ttm) | 0.87 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 5, 2026 |
| Ask | 64.74 |
| Volume | 14,730,512 |
| Avg. Volume (20D) | 1,337,156 |
| Open | 4.50 |
| Previous Close | 4.50 |
| Day's Range | 4.49 - 5.48 |
| 52-Week Range | 4.01 - 54.97 |
| Analyst | Hold |
| Price Target | 6.5 (27.45%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About SION
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector th...
Financial Performance
In 2025, Sionna Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -75.27M, an increase of 22.01%.
Financial StatementsAnalyst Forecast
According to 6 analyst ratings, the average rating for SION stock is "Hold". The 12-month stock price forecast is 6.5, which is upside of 27.45% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
